[New psychopharmacologic alternatives in treatment of schizophrenia].
Clozapine, risperidone and remoxipride are three neuroleptics that represent an interesting alternative in the psychopharmacological treatment of schizophrenia. Pharmacodynamic and pharmacokinetic properties, efficacy, dosages as well as the indication of these three substances are studied. In certain particular situations, a complementary treatment is of important therapeutic use, the addition of benzodiazepines, lithium, carbamazepine or beta-blockers are discussed.
Bryois
C
C
Clinique psychiatrique B Département Universitaire de Psychiatrie Adulte (DUPA), Prilly/Lausanne.
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003024:Clozapine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D010880:Piperidines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D017330:Remoxipride / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D018967:Risperidone; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D007555:Isoxazoles; D010880:Piperidines; D011619:Psychotropic Drugs; D017330:Remoxipride; D003024:Clozapine; D018967:Risperidone